[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyond Air Inc (XAIR)

Beyond Air Inc (XAIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,749
  • Shares Outstanding, K 13,193
  • Annual Sales, $ 3,710 K
  • Annual Income, $ -46,630 K
  • EBIT $ -29 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.26
  • Price/Sales 0.32
  • Price/Cash Flow N/A
  • Price/Book 0.35
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.43
  • Most Recent Earnings $-0.85 on 02/13/26
  • Next Earnings Date 06/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-3.00
  • Growth Rate Est. (year over year) +33,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3345 +7.62%
on 06/16/26
0.5100 -29.41%
on 06/01/26
-0.1210 (-25.16%)
since 05/18/26
3-Month
0.3345 +7.62%
on 06/16/26
0.8209 -56.15%
on 04/10/26
-0.4470 (-55.39%)
since 03/18/26
52-Week
0.3345 +7.62%
on 06/16/26
5.7000 -93.68%
on 06/20/25
-3.6860 (-91.10%)
since 06/18/25

Most Recent Stories

More News
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting

Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information...

XAIR : 0.3600 (-1.91%)
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO)...

XAIR : 0.3600 (-1.91%)
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas...

XAIR : 0.3600 (-1.91%)
Beyond Air to Participate in the D. Boral Capital Global Conference 2026

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide...

XAIR : 0.3600 (-1.91%)
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide...

XAIR : 0.3600 (-1.91%)
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused...

XAIR : 0.3600 (-1.91%)
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic...

XAIR : 0.3600 (-1.91%)
Beyond Air to Participate in the 38th Annual Roth Conference in March

GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing...

XAIR : 0.3600 (-1.91%)
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused...

XAIR : 0.3600 (-1.91%)
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

XAIR : 0.3600 (-1.91%)

Business Summary

Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden...

See More

Key Turning Points

3rd Resistance Point 0.4298
2nd Resistance Point 0.4139
1st Resistance Point 0.3869
Last Price 0.3600
1st Support Level 0.3440
2nd Support Level 0.3281
3rd Support Level 0.3011

See More

52-Week High 5.7000
Fibonacci 61.8% 3.6504
Fibonacci 50% 3.0172
Fibonacci 38.2% 2.3841
Last Price 0.3600
52-Week Low 0.3345

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.